From: Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas
 | N | Fibulin-4(ng/ml) | P | CA-125(U/ml) | P | CA19-9(U/ml) | P |
---|---|---|---|---|---|---|---|
Control | 40 | 29.54 ± 16.17 |  | 33.32 ± 24.55 |  | 35.67 ± 15.59 |  |
Benign | 60 | 38.15 ± 18.43 | >0.05 | 33.16 ± 16.23 | >0.05 | 34.89 ± 17.26 | >0.05 |
Pathology type | Â | Â | >0.05 | Â | >0.05 | Â | >0.05 |
Serous cystadenoma | 25 | 37.26 ± 12.54 |  | 30.51 ± 10.83 |  | 36.85 ± 16.27 |  |
Mucinous cystadenoma | 22 | 36.75 ± 14.32 |  | 35.24 ± 12.69 |  | 33.92 ± 14.78 |  |
Endometrioid tumor | 13 | 39.26 ± 19.73 |  | 32.76 ± 15.93 |  | 31.61 ± 13.41 |  |
Carcinoma | 160 | 267.06 ± 238.71 | <0.05 | 231.60 ± 205.47 | <0.05 | 158.21 ± 124.59 | <0.05 |
Pathology type | Â | Â | >0.05 | Â | <0.05 | Â | <0.05 |
Serous cystadenocarcinoma | 58 | 273.65 ± 215.87 |  | 366.22 ± 216.54 |  | 97.32 ± 31.13 |  |
Mucinous cystadenocarcinoma | 56 | 259.68 ± 211.69 |  | 144.38 ± 95.53 |  | 275.63 ± 107.69 |  |
Endometrioid carcinoma | 46 | 265.72 ± 207.94 |  | 138.46 ± 84.95 |  | 89.86 ± 49.37 |  |
Cell differentiation | Â | Â | <0.05 | Â | <0.05 | Â | <0.05 |
High and Medium | 88 | 104.58 ± 83.86 |  | 123.86 ± 90.22 |  | 87.45 ± 55.36 |  |
Low | 72 | 363.29 ± 239.63 |  | 378.29 ± 197.34 |  | 255.64 ± 158.12 |  |
Tumor stage | Â | Â | <0.05 | Â | <0.05 | Â | <0.05 |
Low stage | 74 | 113.31 ± 96.05 |  | 128.73 ± 85.59 |  | 73.59 ± 40.64 |  |
High stage | 86 | 364.37 ± 243.92 |  | 388.61 ± 216.33 |  | 247.38 ± 146.55 |  |
Nodal status | Â | Â | <0.05 | Â | <0.05 | Â | <0.05 |
Positive | 83 | 353.94 ± 214.37 |  | 376.48 ± 225.64 |  | 268.93 ± 117.32 |  |
Negative | 77 | 101.55 ± 86.81 |  | 131.45 ± 99.56 |  | 92.78 ± 61.19 |  |